CAPTURE工具识别需或无需治疗的慢阻肺患者
基于COMPASS前瞻性研究数据,评估CAPTURE联合呼气峰流速识别慢阻肺患者因症状或急性加重风险而需治疗的能力。结果显示对CAT≥10、mMRC≥2、至少一次中度急性加重或住院的敏感性分别为68.5%、85.6%、63.5%、70.2%,阴性预测值80.8%~95.6%,表明其可较好排除无需治疗者。
要点
- CAPTURE联合呼气峰流速对mMRC≥2的敏感性达85.6%。
- 阴性预测值80.8%~95.6%,有助于排除无需治疗患者。
- 该工具可识别FEV1>60%预计值但需治疗者。
核心结论
- CAPTURE对识别因症状加重或急性加重/住院风险而需治疗的慢阻肺患者具有良好敏感性,高阴性预测值可排除无需治疗者。
研究设计与样本
- 数据来自COMPASS前瞻性研究,纳入慢阻肺患者n=1696、无气流受限的慢性支气管炎患者及健康从不吸烟对照n=307。
- CAPTURE分别以单独问卷及联合呼气峰流速两种方式测试。
主要发现
- 慢阻肺患者平均年龄65±7.5岁,男性90%,支气管舒张后FEV1为66.5±20.1%预计值。
- 对照平均年龄60.2±7.0岁,男性65%,FEV1/FVC比值为0.78±0.04。
- 联合呼气峰流速时,检测CAT≥10的敏感性和特异性分别为68.5%和64.0%。
- 检测mMRC≥2的敏感性和特异性分别为85.6%和61.0%;检测至少一次中度急性加重的敏感性和特异性分别为63.5%和55.6%;检测至少一次住院的敏感性和特异性分别为70.2%和59.4%。
- 阳性预测值范围为15.6%(中度急性加重)至47.8%(CAT评分),阴性预测值范围为80.8%(CAT评分)至95.6%(mMRC评分)。
临床怎么用
- 在初级保健中可用CAPTURE联合呼气峰流速识别可能需治疗的慢阻肺患者,高阴性预测值有助于排除无需治疗者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The CAPTURE tool (Chronic Obstructive Pulmonary Disease [COPD] Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk) was developed to identify patients with undiagnosed COPD with an FEV1 <60% predicted or risk of exacerbation as treatment criteria. Objectives: To test the ability of CAPTURE to identify patients requiring treatment because of symptoms or risk of exacerbation or hospitalization. Methods: Data were from COMPASS (Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China), a prospective study of COPD, chronic bronchitis without airflow limitation (postbronchodilator FEV1/FVC ratio ≥0.70), and healthy never-smokers. CAPTURE was tested as questions alone and with peak expiratory flow measurement. Sensitivity, specificity, and positive and negative predicted values (PPV and NPV) were calculated for COPD Assessment Test (CAT) scores ⩾10 versus <10, modified Medical Research Council (mMRC) scores ⩾2 versus <2, and at least one moderate exacerbation or hospitalization in the previous year versus none. Measurements and Main Results: Patients with COPD (n = 1,696) had a mean age of 65 ± 7.5 years, and 90% were male, with a postbronchodilator FEV1 of 66.5 ± 20.1% predicted. Control participants (n = 307) had a mean age of 60.2 ± 7.0 years, and 65% were male, with an FEV1/FVC ratio of 0.78 ± 0.04. CAPTURE using peak expiratory flow showed the best combination of sensitivity and specificity. Sensitivity and specificity were 68.5% and 64.0%, respectively, to detect a CAT score ⩾10; 85.6% and 61.0% to detect an mMRC score ⩾2; 63.5% and 55.6% to detect at least one moderate exacerbation; and 70.2% and 59.4% to detect at least one hospitalization. PPVs ranged from 15.6% (moderate exacerbations) to 47.8% (CAT score). NPVs ranged from 80.8% (CAT score) to 95.6% (mMRC score). Conclusions: CAPTURE has good sensitivity to identify patients with COPD who may require treatment because of increased symptoms or risk of exacerbations or hospitalization, including those with an FEV1 >60% predicted. High NPV values show that CAPTURE can also exclude those who may not require treatment. Clinical trial registered with www.clinicaltrials.gov (NCT04853225).
引用
- Li, Wen, Ma, et al. Use of CAPTURE to Identify Individuals Who May or May Not Require Treatment for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2023. PMID: 37315325. doi:10.1164/rccm.202303-0504OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。